New Retina Radio by Eyetube Eyetube

Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR severity? Justis Ehlers, MD, breaks down what he and his team uncovered when examining ultra-widefield images from Protocol AA, and helps us understand how machine learning might be used in future retina clinics. And Lisa Faia, MD, explains what her claims database analysis uncovered about the overlap between GA diagnoses and rates of depression and anxiety. What new info do we have that can contextualize the value of GA care?

How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk for PVR and underwent either PPV alone or PPV/scleral buckling. After the break, the doctors discuss the specific mechanics of a PPV/scleral buckle that may lead to successful surgery and ask whether this paper helps us better understand risk factors for PVR.

Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as every 20 weeks without sacrificing efficacy? And even if there are data that suggest that finding, would anyone actually adopt an interval that long in wet AMD patients? Philip Storey, MD, fills us in on TENAYA and LUCERNE data that explored, in part, how many patients could theoretically reach a 20-week dosing interval with faricimab, and which baseline factors predicted whether patients were conducive to such a strategy. And Prof. Sobha Sivaprasad joins us to review findings from PULSAR. In particular, she focuses on data examining whether wet AMD patients could be dosed as long as every 24 weeks on high-dose aflibercept. This is part 1 of 2 of NRR's ARVO 2024 coverage. 

David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD. 

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical relevance of the study's findings.